A total of at least 300 subjects with insulin-requiring type 2 diabetes age 18-80 will be enrolled at up to 25 investigational centers across the United States, using the 780 insulin pump in combination with Guardian 4 sensor and Guardian 4 transmitter.
MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes in a home setting. The combined run-in period and study period will be approximately 135 days long. At the conclusion of the 90-day study period, subjects will be given the opportunity to transition to a period of continued access. They will be allowed to continue using the study device system until further notice from Sponsor.